Survivin; Baculoviral IAP repeat-containing protein 5
CAT No: ta-573
Synonyms/Alias:Survivin (18-27)(modK); Survivin (18-27); Sur18K10; Baculoviral IAP repeat-containing protein 5 (18-27)
Survivin (18-27) is a synthetic peptide fragment derived from the inhibitor of apoptosis protein survivin, specifically encompassing amino acids 18 to 27 of the human survivin sequence. As a member of the inhibitor of apoptosis protein (IAP) family, survivin plays a critical role in regulating cell division and inhibiting apoptotic pathways, making it highly relevant in studies of cell survival, cancer biology, and immune recognition. The 18-27 peptide region represents a well-characterized epitope, frequently investigated for its immunogenic properties and its involvement in antigen presentation, particularly in the context of cytotoxic T lymphocyte (CTL) responses. The unique sequence and biochemical attributes of this peptide have established it as a valuable tool in immunological research, cancer immunotherapy development, and peptide-based assay systems.
Epitope mapping: Researchers utilize the Survivin (18-27) peptide to delineate T cell epitopes, particularly those recognized by HLA-A2-restricted cytotoxic T lymphocytes. By incorporating this peptide into functional assays, investigators can identify and characterize specific immune responses directed against survivin-expressing tumor cells. This approach is instrumental in mapping immunodominant regions within the survivin protein, providing insight into antigen processing and presentation mechanisms that govern cellular immunity.
Immunogenicity assessment: The peptide is frequently employed in ex vivo and in vitro assays to evaluate T cell activation, cytokine production, and cytolytic activity. Its defined sequence enables precise measurement of antigen-specific responses using techniques such as ELISPOT, intracellular cytokine staining, and tetramer analysis. These studies are essential for understanding the immunogenic potential of survivin-derived epitopes and for optimizing peptide-based vaccine strategies targeting malignancies where survivin is overexpressed.
Cancer immunotherapy research: Survivin (18-27) serves as a model antigen in the development and preclinical evaluation of peptide-based immunotherapeutic approaches. By incorporating this peptide into dendritic cell pulsing protocols or synthetic vaccine formulations, investigators can assess its capacity to elicit tumor-specific T cell responses. Such studies contribute to the rational design of immunotherapies that harness the immune system's ability to selectively target survivin-positive cancer cells, thereby advancing translational research in oncology.
Peptide-MHC binding studies: The defined sequence of the Survivin (18-27) peptide makes it a valuable reagent for quantitative and qualitative analyses of peptide-MHC class I interactions. By studying the binding affinity and stability of this peptide with various HLA alleles, researchers can elucidate the molecular determinants of antigen presentation and T cell recognition. These investigations inform the selection of optimal peptide candidates for immunotherapeutic development and facilitate the engineering of improved MHC ligands.
Assay development and standardization: The peptide is widely adopted as a positive control or reference standard in immunological assays designed to monitor antigen-specific T cell responses. Its reproducible immunogenicity and well-characterized sequence enable consistent assay performance across laboratories, supporting the validation and standardization of immune monitoring platforms in both basic research and translational settings. This utility enhances the reliability of data generated in studies of anti-tumor immunity and immunotherapeutic efficacy.
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More